ModeratePharmacokinetic enhancer (booster) for antiretroviral therapy×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
CYP3A4 and CYP3A5 metabolise isavuconazole, and drugs that inhibit these enzymes may raise its blood levels (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Cobicistat is a strong CYP3A inhibitor and acts on this enzyme in a similar way to ritonavir (cobicistat SmPC, EMA). The pair has not been studied directly. On theoretical grounds, the darunavir/cobicistat documents expect isavuconazole levels to rise, and antifungals in turn may raise darunavir and cobicistat levels (darunavir/cobicistat SmPCs, EMA, and prescribing information, US Food and Drug Administration, FDA). Isavuconazole itself is a moderate inhibitor of CYP3A4 and CYP3A5 (EMA). For comparison, lopinavir with ritonavir 100 mg increased isavuconazole exposure (area under the curve, AUC) by 96%, and ketoconazole by 422% (isavuconazole SmPC, EMA, and prescribing information, FDA).
Symptoms
Higher isavuconazole levels may bring more adverse reactions (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). At three times the usual maintenance dose, headache, dizziness, tingling, numbness in the mouth, sleepiness, poor attention, taste disturbance, dry mouth, diarrhoea, vomiting, flushing, anxiety, restlessness, palpitations, fast heart rate, sensitivity to light and joint pain were more frequent (isavuconazole SmPC, EMA, and prescribing information, US Food and Drug Administration, FDA). Isavuconazole shortens the QT interval, more so at higher concentrations, and raised liver enzymes (transaminases) and hepatitis have been reported with it (EMA). The US darunavir/cobicistat label also says to watch for darunavir and cobicistat adverse reactions (FDA).
Management
European documents do not prohibit the combination. Among strong CYP3A4 inhibitors, the European isavuconazole SmPC contraindicates only ketoconazole. With the others, the SmPC keeps the isavuconazole dose unchanged but advises caution, because adverse reactions may increase (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The darunavir/cobicistat SmPCs name isavuconazole and recommend caution and clinical monitoring (darunavir/cobicistat SmPCs, EMA). The US label of the same combination says to monitor for darunavir, cobicistat and antifungal adverse reactions and gives no specific dosing recommendations for the pair (darunavir/cobicistat prescribing information, US Food and Drug Administration, FDA). The US isavuconazole label contraindicates strong CYP3A4 inhibitors, giving ketoconazole and high-dose ritonavir (400 mg every 12 hours) as examples. For lopinavir with ritonavir 100 mg, which nearly doubled isavuconazole exposure, the same label advises caution (isavuconazole prescribing information, FDA). Cobicistat acts on CYP3A in a similar way to ritonavir (cobicistat SmPC, EMA), but the US isavuconazole label does not name cobicistat. Test liver function at the start of and during isavuconazole treatment, and stop isavuconazole if signs of liver disease develop that may be due to it (isavuconazole prescribing information, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3
- EMA: Ficha técnica: Darunavir/cobicistat/emtricitabina/tenofovir alafenamida, Symtuza (EU/1/17/1225), sección 4.5 (2026)– EMA, Symtuza 800 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1171225001, consultada 21.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.5 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: CRESEMBA (isavuconazonium sulfate) prescribing information (2025)– FDA, DailyMed setid 8f7f73b8-586a-4df0-935f-fecd4696c16c (Astellas Pharma US), revisión 04/2025 (versión 21), secciones 4, 5.1, 5.5, 7, 10 y 12.3